Impetigo herpetiformis (IH) is a rare pustular typically occurring during pregnancy. Based upon a similar clinical and histological presentation, i.e. spongiform accumulation of polymorphonuclear leucocytes in the stratum corneum, several authors consider IH as a variant of generalized pustular psoriasis (GPP), while others state that IH is a separate entity. Skin-derived antileucoproteinase (SKALP) is a strong and specific inhibitor of human leucocyte elastase (FILE) and proteinase 3, two neutral proteinases that have been implicated in leucocyte migration and tissue destruction. Previously, we reported decreased SKALP activity in pustular forms of psoriasis compared with plaque psoriasis. In this study we present a case study of a patient with IFI, where SKALP activity was measured using biochemical and immunochemical techniques. Epidermal scales and sera were collected during the course of the disease. Comparison was made with three patients with GPP and six patients with plaque psoriasis. Initially, anti-HLE activity in epidermal scales of the patient with IH was comparable with values in patients with GPP, i.e. decreased compared with plaque psoriasis. During the course of the disease, anti-elastase activity dropped to undetectable levels, concomitant with the appearance of free elastase activity. This ii suggests a total saturation of epidermal anti-HLE activity. Low levels of SKALP, presumably complexed with HLE, could be measured immunochemically in scale extracts. Serum levels of total SKALP correlated with the disease activity. We suggest that a reduced amount of epidermal SKALP contributes to an imbalance between elastase and its inhibitor, resulting in the formation of epidermal pustules. This mechanism of pustule formation could apply both to GPP ; suggesting a final common pathway in the pathogenic mechanisms of IH and GPP.
Impetigo herpetiformis (IH) is a rare pustular dermatosis with unknown aetiology, that typically affects pregnant women. Both the clinical and the histological presenta tion resemble the generalized form of pustular psoriasis. Apart from erythema and scaling, the main character istic of both these conditions is the presence of macro scopic pustules, which are the result of an extreme epidermal infiltration of polymorphonuclear leucocytes (PMN). The pathogenic events leading to the formation of macropustules in these diseases are unknown. Both an increase of epidermal chemotactic factors1'2 and an increased chemotactic response of the PMN} have been implicated as a factor contributing to the massive PMN inllux.
Activated PMN secrete a variety of destructive pro ducts, lor example proteinases (e.g. human leucocyte elastase (FILE) and proteinase 3). One of functions of HLE is to facilitate connective tissue and basal membranes towards inllammatory T activity of proteinases is regulated systemically by numerous plasma-derived inhibitors, such as a i-proteinase a..-macrog We and others have characterized an inducible epider mal proteinase inhibitor, which is absent in normal skin and upregulated in inflammatory skin diseases such as psoriasis.
This inhibitor has been named skin-derived antileucoproteinase (SKALP)/' also known as elalin/ or elastase-speeilic inhibitor (ESI).
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shown to be a potent inhibitor of HLE and proteinase 3. 4 We also showed that SKALP expression by epidermal keratinocytes protects against elastase-mediated loss of cell adhesion. 10 We found that the levels of SKALP in scale extracts from patients with a pustular form, of psoriasis were far lower than in chronic plaque psor iasis. Furthermore, free elastase activity was found in the scale extracts of 25% of the pustular psoriasis patients, a total saturation of epidermal SKALP activity. Based on these findings, we proposed a new mechanism for pustule formation: consumption of SKALP, which is extreme in pustular psoriasis, can lead to local SKALP deficiencies which allow a facili tated migration of PMN, resulting in the formation of pustules.
A similar mechanism for pustule formation could apply to IH. Here we present a case report of a patient with IH, in which we studied the SKALP activity in scale extracts and serum levels during the course of the disease. (Fig. 2) .
In view of the clinical and histological findings, IH was diagnosed. Treatment was started with moderate potency local corticosteroids. The albumin level was psoriasis occur in her family. She was not receiving any medication except for ferrous fumarate because of low haemoglobin.
On the trunk she had polycyclic, confluent, sharply demarcated, bright red lesions with scales and pustule formation (Fig. 1) . The face, inguinal folds, anal region and knee folds were also involved. The pustules did not coalesce: they occurred predominantly at the periphery of the lesions, encircling a central area with desquama tion. The oral cavity was also involved, showing pus tules on the mucosa and tongue. The nails showed no abnormalities. She did not have a fever.
Laboratory investigations showed decreased haemo globin (6*3mmol/L), an increased white blood cell count (20'9 x 10y/L), increased sedimentation rate normalized by an intravenous infusion of 20% albumin solution. Subsequently, the patient was transferred to the department of obstetrics for intensive foetal mon itoring. After 5 days without clinical improvement, therapy was started with prednisone, initially 30 mg daily and later increased to 50 mg daily, and calcitriol, in a dosage of 0*5 fig daily: however, without clinical response. At 3 7 weeks gestation, labour started sponta neously and she delivered a healthy child. Improvement in the skin lesions after delivery was slow: after 2 weeks isotretinoin was started in a dosage of 20 mg daily, and prednisone was gradually reduced over a 3-month period. The pustules and erythema disappeared within 2 weeks from starting isotretinoin. Local emollients were started. After 4 months no skin lesions remained (52 mm in the first hour), normal creatinine, electroand isotretinoin was discontinued. She has remained lytes, glucose and liver enzymes. The phosphate level was low normal, and the calcium level intervals: 0, no pustulation; 1, slight pustulation; 2, moderate pustulation; 3, severe pustulation. Epidermal scales and sera were collected from our patient during the course of the disease. Epidermal scales could only be collected in the initial phase, because later there was insufficient scaling. In addition, epidermal scales were collected from three patients with GPP and six patients with plaque psoriasis. Scales and sera were stored at 20°C for later analysis. Scales were processed for determination of SKALP activity.11 They were weighed, homogenized (100 mg/ mL) in a glass-glass grinder in phosphate-buffered saline (PBS) and centrifuged (15min, 12,000#). The clear' supernatant was divided into two equal portions. One portion was boiled for 2 min to inactivate elastase and to liberate the elastase-bound inhibitor and then centrimm performed the Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Richmond, CA, U.S.A.).
elastase activity in scales
In epidermal scales a direct quantification of the total amount of biologically active SKALP is not possible, because both free elastase and elastase complexed with inhibitor can be found. Our method, used for the measurement of anti-elastase activity in urine, based on the differential heat-stability of elastase and SKALP. Elastase is denatured by boiling the scale extracts for 2 min, whereas SKALP is heat-stable, and 12 
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latent SKALP is released from the enzyme-inhibitor complex. In all scale extracts we measured the free SKALP activity in untreated samples and the total, latent plus free, SKALP activity in heat-inactivated samples. Another complicating factor is the possible presence in human skin of at least two other highaffinity elastase inhibitors beside SKALP, either free or complexed. These are alpha-1-antitrypsin (alpha-1-AT) and secretory leucocyte protease inhibitor (SU 'D, which is identical to antileucoproteinase (ALP).1 } From pre vious studies we know that SLPI activity is present in scales,9 but in relatively low concentration com pared with that of SKALP (unpublished data). Disturb ance by alpha-1-AT activity is eliminated in the assay by the presence of (CTAB).14 Therefore, almost all of the anti-elastase activity measured in our assay represents SKALP activity 
Results
Anti-human leucocyte elastase activity in scale extracts
Using a functional assay we measured the free anti-HLE activity in untreated samples and the total, latent plus free, anti-HLE activity in heat-inactivated samples. In Initially the untreated samples show skin-derived antileucoproteinase (SKALP) activity; however, after 9 days free elastase activity was present in all the following samples, In all those samples, SKALP activity could be recovered after heat inactivation, (b) Anti-HLE activity and SKALP levels in scale extracts of patients with IH (n = .1), generalized pustular psoriasis (GPP) (n = 3), chronic plaque psoriasis (ji= 6). The mean value of 11 samples collected over 20 days was used for the values of the patient with IH (see part (a)). Anti-HLE activity was determined with a functional assay directly (tilled bars) and after heat inactivation (open bars). Heat inactivation releases the SKALP that was complexed with HLE, Note the increase in anti-HLE activity following heat inactivation of scale extracts from the GPP patients and the IH patient. The hatched bars represent SKALP levels as measured with ELISA. SKALP levels were substantially lower in the patient with IH and in the GPP group compared with the plaque psoriasis group. This was found both with functional measurements, which measure anti-HLE activity, and with ELISA techniques, which measure immunoreactive SKALP.
the untreated samples of our patient with IH, anti-HLE activity could be measured during the first 7 days after admission. In all subsequent samples, anti-HLE activity was undetectable, but free elastase activity could be measured. Anti-HLE activity could be detected after heat inactivation ( Fig. 3 a) ; however, the amounts were low compared with that in the patients with plaque psor iasis. In the patients with GPP similar results were found; direct measurement showed free elastase activity factors.16 However, others regard IH as a sepan entity because of its different clinical features and a distinctive typical history.
S K A L P A N D IM P E T ï G 0 H E R P E TIF
Our pi with the characteristic clinical signs of IH. She had no history of skin disorders until her third pregnancy. In contrast with reports in the literature, her skin did not clear quickly after the delivery. Treatment with isotreti noin was starte As IH presents during pregnancy, there is probably an aetiological relationship between 111 and nancy. After IH has once affected a pati presentation in each subsequent pregnancy has been
reported, induce IH in Oral contracep ti ve previously to in pathological mechanism has been determined so far. Hypocalcaemia is presumed to be of importance; it has been associt in two of the three patients, whereas heat-inactivation liberated the anti-HLE activity. Anti-HLE values in IH and GPP were in the same range. In the patients with plaque psoriasis no free elastase activity was present, and total anti-HLE activity was high compared with that in patients with IH and GPP (Fig. 3b) .
SKALP levels in scale extracts and in serum
In order to study the SKALP levels without possible interference by other elastase inhibitors, we used a specific sandwich-type ELISA. SKALP levels, as measured with ELISA in the supernatant of boiled scale extracts, were higher than those obtained with the functional assay (Fig. 3b) . This is probably due to the fact that in the ELISA both biologically active intact SKALP and degraded SKALP are measured. As with the functional assay, the SKALP concentration was signifi cantly lower in IH and in GPP compared with plaque In the serial serum Sc measured SKALP Serum s of our patient with IH we using the ELISA technique. of SKALP correlated with ■ "" a s e activity shown by the formation of pustules (Fig. 4) .
, followed by a reduction of SKALP levels to normal values. with IH."" Patients with GPP and psoriasis vulgaris can experience reactivation of their disease during episodes of hypocalcaemia.
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One report of GPP patients found hypocalcaemia in only live of 57 patients, and it was not found in subsequent equally severe periods of disease. The authors suggested that hypocalcaemia is a secondary phenomenon, due to a transient state of 
Discussion
It is still a matter of debate whether IH should be considered as a separate entity or as a variant of GPP. Some authors consider both to be the result of a final common pi ay by i ent pathogenic it in g a course of the disease. Most striking was the lack of free anti-HLE activity from 9 days after i these samples free HLE activity was found, i total saturation of all available anti-HLE ac heat inactivation, anti-HLE activity was found, due to the liberation of SKALP from its complex with HLE. However, the amount of total anti-HLE activity is lower 12 by a factor of 5 than in plaque psoriasis. In the three patients with GPP we found similar results. We suggest that the local deficiency of SKALP as found in IH and GPP facilitates PMN migration into the epidermis, lead ing finally to a massive accumulation of PMN in the epidermis. It is not clear which mechanism leads to the decreased levels of SKALP. In keratotome biopsies of patients with plaque psoriasis and pustular psoriasis, no difference was seen in SKALP expression at the mRNA level.11 Whether the decrease of SKALP is caused by an enhanced inactivation and subsequent clearance needs to be studied in the future. As SKALP is a cationic, low molecular weight protein, it can easily cross the basal membrane, penetrate the connective tissue and reach the circulation. SKALP can be demonstrated in the urine of psoriatic patients. Furthermore, we have reported a correlation of serum SKALP levels with disease activity in patients with 5 { A psoriasis who were treated with cyclosporin A. In our patient serum levels of SKALP correlated well with the pustulation; however, the decrease of SKALP lags slightly behind the clearance of the pustules. Compared with patients with plaque psoriasis with a similar area of skin affected, the SKALP levels in IH are rather low (not shown).
In the patient with IH we have demonstrated a dynamic variation of SKALP in scales and serum during the course of the disease. In scales, anti-elastase activity dropped to undetectable levels, while free elas tase activity appeared. Serum levels of SKALP correlated with the disease activity. We suggest that in both GPP and IH a final common pathway is involved in the pathogenic mechanism of pustule formation. In both diseases a deficiency of SKALP could be of importance in pustule formation. These findings would imply that in both GPP and IH the use ol' a low molecular weight drug with anti-elastase activity could be a new therapeutic modality.
